-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Elobixibat is an ileal bile acid transporter (IBAT) inhibitor that reduces bile reabsorption, which in turn reduces fat accumulation in the liver
.
Improvements in these indicators are important for relieving liver scarring and inflammation, as well as inhibiting fat and blood sugar elevations.
Elobixibat is an ileal bile acid transporter (IBAT) inhibitor that reduces bile reabsorption, which in turn reduces fat accumulation in the liver
The researchers collected healthy subjects (n = 10) and patients with chronic constipation (n = 19) for a 7-day hospitalization, during which they received meals containing about 60 grams of fat
.
Patients with chronic constipation continued to be hospitalized for 7 days with once-daily elobixibat dosing
The findings showed that fecal total and primary bile acids were significantly lower in patients with chronic constipation compared with healthy subjects
.
Serum C4 and fibroblast growth factor levels were comparable between groups
Therefore, the study authors concluded that despite comparable C4 levels, fecal bile acid levels were lower in patients with chronic constipation compared with healthy subjects
.
Elobixibat treatment increases fecal bile acid excretion and decreases serum bile acid concentrations
Therefore, the study authors concluded that despite comparable C4 levels, fecal bile acid levels were lower in patients with chronic constipation compared with healthy subjects
Original source:
Atsushi Nakajima.
leave a message here